Article

FDA accepts Sirion NDA, license acquisition

The FDA has accepted Sirion Therapeutics' new drug application (NDA) for difluprednate ophthalmic emulsion 0.05% (Durezol) and has granted it priority review, the Tampa, FL-based company has announced.

Rockville, MD-The FDA has accepted Sirion Therapeutics' new drug application (NDA) for difluprednate ophthalmic emulsion 0.05% (Durezol) and has granted it priority review, the Tampa, FL-based company has announced.

The steroid has been tested as a twice-daily treatment for postoperative ocular inflammation. Under the priority review process, the start date for the 6-month review is the date of receipt of the NDA. The FDA has issued an action date of June 26.

Data from two phase III clinical studies of difluprednate will be presented at the annual meeting of the American Society of Cataract and Refractive Surgery next month in Chicago.

Under the terms of this licensing agreement, Sirion will have the rights to manufacture, sell, and distribute norketotifen for ocular use either alone or in combination with other drugs. Clinical trials of the drug are expected to begin in early 2009.

"We are very excited about the medical and market potential of the norketotifen molecule," said Roger Vogel, MD, chief medical officer of Sirion.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.